Mizuho Securities analyst Difei Yang maintained a Buy rating on Zogenix (ZGNX) today and set a price target of $69. The company’s shares closed on Tuesday at $43.87.
“We continue to see Fintepla as highly differentiated from competitor products with the potential for higher pricing and market share. The most important catalyst is a potential FDA approval in DS in 2019. Beyond DS, we see potential for for which data is anticipated in 1Q20.”
According to TipRanks.com, Yang is a 5-star analyst with an average return of 17.8% and a 46.3% success rate. Yang covers the Healthcare sector, focusing on stocks such as Alder Biopharmaceuticals, Audentes Therapeutics, and Revance Therapeutics.
Zogenix has an analyst consensus of Strong Buy, with a price target consensus of $75.
See today’s analyst top recommended stocks >>
Based on Zogenix’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $42.26 million. In comparison, last year the company had a GAAP net loss of $42.79 million.
Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is neutral on the stock. Most recently, in October 2018, Erle Mast, a Director at ZGNX bought 1,468 shares for a total of $39,360.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Zogenix, Inc. is a pharmaceutical compan. It engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include ZX008 and Relday.